Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Trial Profile

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Granulocyte colony-stimulating factors; Nivolumab; Vinblastine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 06 Nov 2019 Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 23 Sep 2019 Phase changed from phase 4 to phase 2, one arm has been added, drug nivolumab has been added, hence the protocol was amended.
    • 23 Sep 2019 Planned number of patients changed from 180 to 90.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top